Article: Sepracor Reports That Schering-Plough Applies For Broader Clarinex(TM) Indication in United States For Treatment of Allergic Rhinitis.

Broader Claim Covers Seasonal Allergic Rhinitis and Perennial Allergic

Rhinitis

MARLBOROUGH, Mass., April 16 /PRNewswire/ --

Sepracor Inc. (Nasdaq: SEPR) today reported that Schering-Plough Corporation (NYSE: SGP) has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking to broaden the allergy indication for its nonsedating antihistamine, CLARINEX(TM) (desloratadine) 5 mg Tablets. The proposed indication of allergic rhinitis would encompass both seasonal allergic rhinitis (SAR) and perennial allergic rhinitis (PAR). The allergic rhinitis NDA is based on eight randomized, placebo-controlled studies ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!